Neurocrine Biosciences Inc (NBIX) Stock Up 3.7% and Still Undervalued -- GF Score: 90/100

gurufocus.com · 2026-10-20

On October 20, 2026, Neurocrine Biosciences Inc (NBIX) shares rose 3.7% to $142.00, bouncing back within a 52-week range between $122.14 and $186.12. This recen

TickrTrends take: Neurocrine Biosciences trades with a GF Score of 90 out of 100, indicating strong fundamental quality metrics that align with TickrTrends' undervalued assessment. For investors focused on valuation in the Healthcare sector, the combination of a high quality score and undervalued status suggests the stock may offer margin of safety at current price levels. Monitoring whether NBIX maintains this valuation gap as the stock moves could help determine if the disconnect between quality and price persists or narrows.

Read the full story at gurufocus.com →